financetom
Business
financetom
/
Business
/
US official pressures Panama over Chinese businesses near the canal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US official pressures Panama over Chinese businesses near the canal
Feb 2, 2025 1:25 PM

PANAMA CITY (Reuters) - U.S. top diplomat Marco Rubio warned Panama to immediately take steps to address U.S. concerns over Chinese businesses operating ports near the canal, which President Donald Trump has said represent a threat to U.S. national security.

The U.S. and Panama made progress on key migration and business issues during Rubio's visit in Panama City, but failed to find common ground over the Panama Canal's operations, with President Jose Mulino saying his country's sovereignty over the world's second busiest waterway is not up for discussion.

"Trump has made a preliminary determination that the current position of influence and control of the Chinese Communist Party over the Panama Canal area is a threat to the canal," said U.S. State Department spokesperson Tammy Bruce.

Trump has refused to rule out use of military force over Panama, drawing criticism from Washington's Latin American friends and foes alike. In a senate hearing last week, U.S. officials said fines and restrictions on Panamanian-flag vessels entering U.S. ports could be imposed due to the dispute over the canal.

Following his meeting with Rubio, which he said was respectful and cordial, Mulino announced that a memorandum of understanding signed in July with the U.S. Department of Homeland security could be expanded so Venezuelans, Colombians and Ecuadoreans can be returned from the perilous Darien Gap at U.S. cost, through an airstrip in Panama.

Mulino also showed willingness to review some Chinese businesses in Panama, including a key 25-year concession to Hong Kong-based CK Hutchison Holdings ( CKHUF ), renewed in 2021 for the operation of ports at both entrances of the canal, pending the results of an audit.

The contract has been targeted by U.S. lawmakers and the government as an example of China's expansion in Panama, which they claim goes against a neutrality treaty signed by both countries in 1977.

Panama's government and some experts reject that assertion, mainly because the ports are not part of the canal's operations and have not represented a security issue.

A broad agreement between Panama and China to contribute to China's silk road program, under which the Asian country expanded investment in Panama during previous administrations, will not be renewed, Mulino said.

"We'll study the possibility of terminating it early," he added.

Mulino also said it will be "important" to have face-to-face talks with Trump over key issues.

FIRST TOUR

The U.S. secretary of state is touring Central America and the Caribbean on his first foray in the post as he seeks to refocus U.S. diplomacy on the Western Hemisphere - in part to recruit help in stemming migration toward the U.S. southern border.

The visit also reflects a U.S. desire to counter China's growing economic and political influence in Latin America.

Trump upon returning to office threatened to take control of Panama Canal, built by the United States in the early 20th century and handed over to Panama in 1999, claiming the canal is being operated by China.

China has said it plays no part in operating the canal and that it respects Panama's sovereignty and independence over the waterway.

The canal is operated by the Panama Canal Authority, an autonomous agency overseen by the Panamanian government.

Rubio, a longtime China hawk during his Senate career, said last week that China could use the ports to shut down the canal, a vital route for U.S. shipping, in the event of a conflict between Beijing and Washington.

Rubio has ordered the State Department to put migration issues at the center of its diplomacy with countries in the region. Officials have said Rubio will use the trip to smooth the acceptance of U.S. deportation flights to the region.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intchains to Raise $1 Million Via Direct Offering
Intchains to Raise $1 Million Via Direct Offering
Mar 26, 2025
08:30 AM EDT, 03/26/2025 (MT Newswires) -- Intchains Group ( ICG ) said Wednesday it has entered into a securities purchase agreement with an institutional investor for a direct offering of 361,011 American depositary shares, each representing two class A ordinary shares, priced at $2.77 per American depositary shares for gross proceeds of $1 million. The provider of altcoin mining...
Lightspeed Commerce Releases Growth Projections, Renews Share Reauthorization
Lightspeed Commerce Releases Growth Projections, Renews Share Reauthorization
Mar 26, 2025
08:32 AM EDT, 03/26/2025 (MT Newswires) -- Lightspeed Commerce ( LSPD ) said Wednesday it expects fiscal 2026 to fiscal 2028 consolidated gross profit growth at a three-year total compounded annual rate of about 15% to 18%, reaching around $700 million. Within its primary growth engines, the provider of point-of-sale software for retail outlets said it expects gross profit growth...
Carter's Names Douglas Palladini as CEO
Carter's Names Douglas Palladini as CEO
Mar 26, 2025
08:33 AM EDT, 03/26/2025 (MT Newswires) -- Carter's (CRI) said Wednesday it has appointed Douglas Palladini as president and chief executive of the company, effective April 3. Palladini most recently served as founder and owner of consulting firm Kickstand, Carter's said, adding that the new CEO will also become a board member. ...
Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial
Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial
Mar 26, 2025
08:31 AM EDT, 03/26/2025 (MT Newswires) -- Leap Therapeutics ( LPTX ) said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer. Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved